LIGAND PHARMACEUTICALS INCORPORATED
NASDAQ: LGND (Ligand Pharmaceuticals Incorpor)
Last update: 5 hours ago285.60
-4.14 (-1.43%)
| Previous Close | 289.74 |
| Volume | 132,389 |
| Price / Earnings (Forward) | 25.71 |
| Price / Sales | 21.38 |
| Price / Book | 5.97 |
| 52 Weeks Range |
| Profit Margin | -73.07% |
| Operating Margin (TTM) | -80.87% |
| Diluted EPS (TTM) | -7.29 |
| Quarterly Revenue Growth (YOY) | 46.30% |
| Total Debt/Equity (MRQ) | 0.56% |
| Current Ratio (MRQ) | 5.27 |
| Operating Cash Flow (TTM) | 52.87 M |
| Levered Free Cash Flow (TTM) | 63.35 M |
| Return on Assets (TTM) | -1.14% |
| Return on Equity (TTM) | -16.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ligand Pharmaceuticals Incorpor | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.33 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 100.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Franklin Templeton Inc | 30 Jun 2026 | 752,044 |
| Congress Asset Management Co | 30 Jun 2026 | 659,911 |
| Nomura Investment Management Business Trust | 30 Jun 2026 | 568,371 |
| Chicago Capital, Llc | 30 Jun 2026 | 553,435 |
| Stephens Investment Management Group Llc | 30 Jun 2026 | 475,609 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |